Daprodustat is a novel orally administrated active hypoxia-induced factor-prolyl hydroxylase inhibitor (HIF-PHI) that may improve quality of life and ischemic conditions such as peripheral arterial disease (PAD), stimulate the synthesis of endogenous EPO, and can effectively induce the production of red blood cells. The gene discussed is EPO; the disease is peripheral arterial disease.